Mikolow

Atopic dermatitis is a chronic condition causing skin irritation, redness, and itchiness. This trial evaluates the effectiveness and safety of methotrexate, a drug approved for other conditions like arthritis and psoriasis, compared to placebo in adults with moderate to severe atopic dermatitis. The study aims to provide more systemic treatment options for those who do not respond well to topical therapies. It is a Phase 3, randomized, double-blind, placebo-controlled trial. Participants will receive either methotrexate or a placebo via injection using a prefilled pen. The treatment is administered subcutaneously, and the study monitors participants over a 16-week period. The primary measurement is the Eczema Area and Severity Index (EASI) 75 response at week 16, which assesses improvement in skin condition. The trial includes detailed eligibility and safety monitoring protocols. During the study, participants will be regularly evaluated for their skin condition and overall health. Researchers will collect data on eczema severity, quality of life, and any side effects. Safety assessments include laboratory tests and chest X-rays before starting treatment. Participants must comply with study requirements and attend scheduled visits over the trial duration to help researchers determine the treatment's efficacy and safety.

Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis. This Phase 3b/4 study focuses on participants who are candidates for phototherapy or systemic treatment and have specific cardiovascular risk factors such as smoking, hypertension, diabetes, obesity, or a family history of heart disease. Participants will receive either Deucravacitinib or Ustekinumab at specified doses on set days. This open-label, randomized study compares these treatments over an extended period to monitor their safety profiles, including cardiovascular health. Throughout the study, researchers will track major adverse cardiovascular events, including heart attacks, strokes, and related procedures, for up to five years. Participants will undergo regular assessments to monitor their psoriasis and cardiovascular status, ensuring comprehensive safety evaluation during the long-term treatment.